DiscoverRegWatch by RegulatorWatch.comRISK PROFILE | FDA Authorizes Zyn But Keeps Vapes in Limbo | RegWatch
RISK PROFILE | FDA Authorizes Zyn But Keeps Vapes in Limbo | RegWatch

RISK PROFILE | FDA Authorizes Zyn But Keeps Vapes in Limbo | RegWatch

Update: 2025-03-11
Share

Description

Earlier this year, the U.S. Food and Drug Administration granted marketing orders for 20 Zyn flavored nicotine pouch products—the first time the agency has authorized such products. The decision left many in the vaping world stunned—not just by the range of flavors greenlit, from cinnamon and citrus to coffee and peppermint—but by the FDA’s continued foot-dragging on e-cigarette approvals. Why the disparity when both pouches and vapes are considered safer nicotine alternatives?


Joining us to break it all down is Kevin Schroth, J.D., Associate Professor at Rutgers School of Public Health and the Institute for Nicotine and Tobacco Studies. Find out why the FDA’s uneven treatment of these products comes down to a risk-benefit analysis entirely focused on youth. What does this mean for the future of vaping?


Find out—only on RegWatch by RegulatorWatch.com.


https://youtu.be/gJicJ76To7w


Released: March 10, 2025

Produced by: Brent Stafford


Make RegWatch happen, go to https://support.regulatorwatch.com


#RegWatch #VapeNews

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

RISK PROFILE | FDA Authorizes Zyn But Keeps Vapes in Limbo | RegWatch

RISK PROFILE | FDA Authorizes Zyn But Keeps Vapes in Limbo | RegWatch

Brent Stafford